Alexandria Pharmaceuticals results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit31.71 millionEGP · +31.6% vs the same period a year earlier
Total assets994 millionEGP · +13.4% vs the same period a year earlier
Shareholders' equity610 millionEGP · +5.7% vs the same period a year earlier
Operating cash flow100 millionEGP · +115.7% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Q2 2023 was about 31.71 million EGP, up +31.6% from 24.08 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 994 million EGP, and shareholders' equity about 610 million EGP.
- Operating cash flow for Q2 2023 was positive at 100 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit31.71 million24.08 million+31.6%
Gross profit67.59 million60.69 million+11.4%
Total assets994 million876 million+13.4%
Total liabilities384 million300 million+28.3%
Shareholders' equity610 million577 million+5.7%
Total liabilities and equity994 million876 million+13.4%
Operating cash flow100 million46.44 million+115.7%
Investing cash flow-13.76 million-6.82 million−101.6%
Financing cash flow-47.49 million-33.23 million−42.9%
Net change in cash38.93 million6.39 million+509.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy